Zillow Group(Z)
Search documents
Zillow shares pop on earnings, CEO announcement
Proactiveinvestors NA· 2024-08-08 19:41
About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...
Zillow's (ZG) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
ZACKS· 2024-08-08 17:20
Zillow Group, Inc. (ZG) reported healthy second-quarter 2024 results, wherein both the top and bottom lines surpassed the Zacks Consensus Estimate. The company witnessed a revenue expansion year over year, backed by strong momentum in all verticals.The company has a solid brand position in the residential real estate industry. It boasts 231 million average monthly unique users across the Zillow ecosystem of apps and sites. Zillow’s advanced technology, such as Real Time Touring, Listing Showcase, Follow Up ...
Zillow (ZG) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
ZACKS· 2024-08-08 01:30
Zillow Group (ZG) reported $572 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 13%. EPS of $0.39 for the same period compares to $0.39 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $539.75 million, representing a surprise of +5.98%. The company delivered an EPS surprise of +25.81%, with the consensus EPS estimate being $0.31.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...
Zillow (Z) Q2 Earnings and Revenues Surpass Estimates
ZACKS· 2024-08-07 22:55
Zillow (Z) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.81%. A quarter ago, it was expected that this real estate website operator would post earnings of $0.36 per share when it actually produced earnings of $0.36, delivering no surprise.Over the last four quarters, the company ...
Zillow Group (ZG) Surpasses Q2 Earnings and Revenue Estimates
ZACKS· 2024-08-07 22:55
Zillow Group (ZG) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.81%. A quarter ago, it was expected that this online real estate marketplace would post earnings of $0.36 per share when it actually produced earnings of $0.36, delivering no surprise.Over the last four quarters, the ...
Zillow Group(Z) - 2024 Q2 - Quarterly Results
2024-08-07 20:05
Exhibit 99.2 Reported Consolidated Results ZILLOW GROUP, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, unaudited) | --- | --- | --- | |--------------------------------------------------|---------------|--------------| | | | December 31, | | | June 30, 2024 | 2023 | | Assets | | | | Current assets: | | | | Cash and cash equivalents | $ 1,181 | 1,492 | | Short-term investments | 1,447 | 1,318 | | Accounts receivable, net | | 96 | | Mortgage loans held for sale | | 100 | | Prepaid expenses and other ...
Zillow Group(Z) - 2024 Q2 - Quarterly Report
2024-08-07 20:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 10-Q _____________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36853 _____________________________________________________ ZILLOW G ...
Luxury home values are rising faster than typical homes for the first time in years
Prnewswire· 2024-07-31 12:00
Listings for luxury homes are seeing relatively more competition than homes in the market's midrange Luxury home values are up 3.9% year over year. Inventory of luxury homes remains 46.9% below pre-pandemic levels, a bigger deficit than in the housing market overall. Richmond has the hottest luxury housing market in the country. Austin is the only major market where luxury home values have declined throughout the past year. SEATTLE, July 31, 2024 /PRNewswire/ -- Luxury home value growth, which has consis ...
A $1 million starter home? It's the norm in 237 cities
Prnewswire· 2024-07-25 12:03
The number of cities with 'million-dollar' starter homes has nearly tripled since 2019 The number of cities where a starter home is worth $1 million or more has grown from 84 five years ago to 237 today. Nearly half of these cities with "million-dollar" starter homes are in California. The typical starter home nationwide is worth less than $200,000. SEATTLE, July 25, 2024 /PRNewswire/ -- A million-dollar price tag no longer means lavish and luxurious living. In more than 200 U.S. cities, buyers will find a ...
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
GlobeNewswire News Room· 2024-07-22 12:30
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa’s patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 E ...